What was known before {#section19-2054358118778568}
=====================

Polycystic kidney disease is associated with progression to end-stage kidney disease often over the course of decades. European and US dialysis registries report a higher frequency of transplantation, home dialysis, and arteriovenous fistula use. However Canadian data are lacking.

What this adds {#section20-2054358118778568}
==============

Adults with polycystic kidney disease in Canada are more likely to receive a kidney transplant, be on home hemodialysis (but not peritoneal dialysis), be dialyzed with an arteriovenous fistula, and have improved survival compared with non-ADPKD patients.

Background {#section21-2054358118778568}
==========

Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease, affecting between 1:800 and 1:1000 people.^[@bibr1-2054358118778568]^ ADPKD is characterized by cystic expansion of the kidneys, progressing to bilateral kidney enlargement, and various degrees of chronic kidney disease.^[@bibr2-2054358118778568]^ In addition, many patients experience flank and/or abdominal pain, hematuria, hypertension, and other related symptoms.^[@bibr3-2054358118778568]^ With \~50% of ADPKD patients progressing to end-stage kidney disease (ESKD) by age 70 years, ADPKD accounts for 5% to 10% of all patients requiring renal replacement therapy (RRT).^[@bibr4-2054358118778568],[@bibr5-2054358118778568]^ As such, it is essential to understand standard practice regarding the treatment of end-stage ADPKD via RRT.

In patients progressing to ESKD, studies have already shown superior outcomes in the survival of ADPKD patients on RRT vs non-ADPKD patients; furthermore, recent literature suggests that a disparity exists not only in survival but also in the choices of treatment strategies between these two matched cohorts.^[@bibr4-2054358118778568][@bibr5-2054358118778568]-[@bibr6-2054358118778568]^ With this in mind, information retrieved from the Canadian Organ Replacement Register (CORR) can highlight RRT trends in Canada and elucidate differences in treatment decisions for the ADPKD vs non-ADPKD populations progressing to ESKD. Detailed information regarding RRT modality choices and clinical outcomes specific to ADPKD may improve treatment guidelines and advance our current knowledge of this patient group.^[@bibr7-2054358118778568]^

The aim of our study is to examine the association of ADPKD status with the use of home modalities, vascular access, and preemptive transplantation as compared with non-ADPKD. Clinical outcomes including the risk of all-cause mortality in these groups will be assessed broadly for all ESKD patients, as well as for the specific dialysis and vascular access subtypes.

Methods {#section22-2054358118778568}
=======

Design and Setting {#section23-2054358118778568}
------------------

We conducted a registry-based retrospective cohort study in Canada (excluding Quebec) using data from the CORR. The study was conducted according to a prespecified protocol that was approved by the Research Ethics Board at The Ottawa Hospital (Ottawa, Ontario, Canada).

Study Population and Cohort Development {#section24-2054358118778568}
---------------------------------------

All adult incident patients requiring chronic renal replacement and captured by the CORR from January 1, 2001, to December 31, 2012, were included in the study cohort. CORR is a national administrative registry and is administered by the Canadian Institute for Health Information (CIHI).^[@bibr8-2054358118778568]^ CORR captures patient-level treatment and outcomes data for individuals on RRT including demographics, comorbidities, receipt of kidney transplantation, dialysis modality, vascular access, and follow-up.^[@bibr9-2054358118778568]^ CORR receives data from individual facilities using standardized forms or spreadsheets and is reported on a calendar-year basis. CORR captures the vast majority of incident RRT patients with validation studies reporting 93% of dialysis patients and 98% of transplantation patients.^[@bibr10-2054358118778568]^ Data are collected until death, loss of follow--up, or end of the study period.

Exposure, Comorbidities, and Outcomes {#section25-2054358118778568}
-------------------------------------

The exposure of interest was ADPKD that was defined as adult-type ADPKD as the treating physician's diagnosis. Comorbidities (acute coronary syndrome, diabetes \[not cause of ESKD\], stroke, peripheral vascular disease, coronary artery bypass graft, cancer, chronic obstructive pulmonary disease, hypertension, congestive heart failure, cigarette smoker, and any serious illness) were defined by the treating physician at the time of chronic dialysis initiation. Laboratory values (hemoglobin, albumin, phosphate, calcium) were recorded at the initiation of dialysis. Serious illness was defined as any illness that could shorten life expectancy to less than 5 years and is used to capture illnesses other than the usual comorbidities in CORR that may alter survival. Predialysis care was defined as receipt of care by a nephrologist prior to dialysis initiation. Distance to facility was calculated as the direct linear distance in kilometers between a patient's primary residence (estimated from postal code at time of dialysis initiation) to the nearest dialysis provider using Vincenty's formula.^[@bibr11-2054358118778568]^ The year of dialysis initiation, self-identified race, and geographic region were also captured. Missing data were as follows: cause of ESKD (5.9%), predialysis care (15.6%), albumin (14.9%), phosphate (13%), and calcium (12.1%).

The study outcomes of interest were (1) initial type of RRT (transplant, peritoneal dialysis \[PD\], intermittent in-center hemodialysis, short daily hemodialysis, or nocturnal hemodialysis), (2) initial vascular access (arteriovenous fistula \[AVF\], permanent central catheter, or temporary central catheter), and (3) all-cause mortality. Short daily or nocturnal hemodialysis could be either in-center or home-based. For all-cause mortality, patients were followed until death (event of interest) or the end of study (a censoring event).

Type of RRT was defined 2 ways: (1) at ESKD onset and (2) during any time on ESKD. Vascular access was categorized as AVF, permanent CVC, or temporary CVC. arteriovenous graft (AVG) use in Canada is relatively infrequent, comprising less than 2% of total vascular accesses and was categorized as AVF.^[@bibr12-2054358118778568],[@bibr13-2054358118778568]^ Patients with more than one type of vascular access listed (eg, CVC and AVF) were categorized as CVC.

Statistical Analysis {#section26-2054358118778568}
--------------------

We used propensity score (PS) matching to match individuals with ADPKD to individuals without ADPKD using the following variables in our model: age (per year), sex (male referent), year of ESKD, distance from facility, predialysis care, comorbidities at baseline (acute coronary syndrome, diabetes \[not cause of ESKD\], stroke, peripheral vascular disease, coronary artery bypass graft, cancer, chronic obstructive pulmonary disease, hypertension, congestive heart failure, cigarette smoker, and any serious illness\], and laboratory values at baseline (hemoglobin, calcium, phosphate, albumin). Individuals with ADPKD were matched 1:4 to individuals without ADPKD on the logit of the PS (±0.0.1 of the standard deviation) without replacement.^[@bibr14-2054358118778568]^ We used standardized differences to assess differences in baseline characteristics between matched individuals by ADPKD status. Standardized differences describe differences between group means relative to the pooled standard deviation and are less sensitive to large sample sizes than traditional hypothesis testing.^[@bibr15-2054358118778568]^ A difference \>10% was considered meaningful. We examined the association of ADPKD exposure on PS-matched pairs and the outcomes of kidney transplant, dialysis modality, and dialysis access at the initiation of ESKD or any time during ESKD using conditional logistic regression.^[@bibr16-2054358118778568]^ In a sensitivity analysis, we repeated our models with additional adjustments for covariates that were not balanced after PS matching (race, geographic region, predialysis care, hypertension, hemoglobin, and albumin).^[@bibr14-2054358118778568]^ All-cause mortality was modeled using stratified Cox proportional hazards models for patients whose initial ESKD modality was intermittent hemodialysis (IHD) or PD. The proportional hazards assumption was examined and met.^[@bibr17-2054358118778568]^

To avoid exclusion of subjects due to missing covariates, multiple imputation was performed prior to analysis. The imputations were generated using a Markov Chain Monte Carlo algorithm (the data augmentation algorithm).^[@bibr18-2054358118778568]^ Ten multiple imputation data sets were generated with all variables included in analytical models specified as predictors in the multiple imputation model. Analyses were carried out for each multiple imputation data set and pooled across data sets using Rubin's rules.^[@bibr19-2054358118778568]^ All analyses were conducted with SAS 9.4. All hypothesis tests were 2 sided with statistical significance determined at a *P* value of \<.05.

Results {#section27-2054358118778568}
=======

Between January 1, 2001, and December 31, 2015, a total of 52 121 patients registered in the Canadian Organ Replacement Registry received RRT, comprising of 2122 ADPKD patients and 50 029 non-ADPKD patients. Of these patients, the average age was 56.7 years for ADPKD and 64.1 years for non-ADPKD patients, with 46.1% and 39.9% being female in each group, respectively (see [Table 1](#table1-2054358118778568){ref-type="table"}). Prior to matching, there were significant differences between the two groups in terms of predialysis care, race, geographic region, comorbidities (vascular disease, diabetes, cancer, any serious illness), and laboratory values (hemoglobin, albumin) as indicated by a SD \> 0.10. After PS matching, all covariates were well balanced except for race, geographic region, predialysis care, hypertension, hemoglobin, and albumin. Four matches for each ADPKD patient were obtained in 97.7% of cases, whereas 197 ADPKD cases had only 3 matches.

###### 

Demographics, Comorbidities, and Relevant Laboratory Values of ADPKD and Non-ADPKD Patients With End-Stage Kidney Disease Requiring Renal Replacement Therapy.^[a](#table-fn2-2054358118778568){ref-type="table-fn"}^

![](10.1177_2054358118778568-table1)

                                                                  Total cohort (N = 52 151)   PS-matched (N = 10 403)                                                          
  --------------------------------------------------------------- --------------------------- ------------------------- ---------- --------------------- --------------------- ----------
  N                                                               2122                        50029                                2120                  8283                  
  Age (years, mean)                                               56.7 (SD 12.3)              64.1 (SD 15.4)            **0.53**   56.7 (SD 12.3)        57.4 (SD 18.3)        0.04
  Sex (female, %)                                                 46.1 (978)                  39.9 (19 961)             0.13       46.0 (976)            46.2 (3828)           0.003
  Distance to facility (median, km)                               15.4 (IQR 5.8-63.6)         11.0(IQR 4.7-47.1)        0.04       15.4 (IQR 5.7-63.6)   11.7 (IQR 5.1-45.8)   0.01
  Any predialysis care (%, n)                                     80.3 (1703)                 84.5 (42 297)             0.11       80.2 (1701)           87.8 (7276)           **0.21**
  Race                                                                                                                  **0.36**                                               **0.36**
   Caucasian                                                      80.4 (1705)                 69.3 (34 620)                        80.4 (1704)           68.1 (5642)           
   East Asian                                                     3.1 (65)                    6.6 (3281)                           3.1 (65)              8.1 (669)             
   Black                                                          2.4 (50)                    3.4 (1676)                           2.4 (50)              3.9 (325)             
   South Asian                                                    3.1 (65)                    4.4 (2216)                           3.1 (65)              4.5 (373)             
   Indigenous                                                     0.9 (19)                    6.0 (2983)                           0.9 (19)              3.6 (374)             
   Other                                                          10.2 (216)                  10.4 (5199)                          10.2 (217)            10.9 (900)            
  Year                                                                                                                  0.07                                                   0.05
   2001-2004                                                      31.8 (652)                  30.9 (15 459)                        31.8 (650)            32.1 (2661)           
   2005-2008                                                      36.2 (767)                  33.0 (16 511)                        36.2 (767)            33.6 (2783)           
   2009-2012                                                      33.2 (703)                  36.0 (18 005)                        33.2 (703)            34.3 (2839)           
  Region^[b](#table-fn3-2054358118778568){ref-type="table-fn"}^                                                         **0.15**                                               **0.16**
   Atlantic                                                       14.1 (298)                  9.5 (4760)                           14.1 (298)            9.1 (752)             
   Central                                                        48.7 (1035)                 52.8 (26 378)                        48.7 (1033)           53.1 (4395)           
   Prairies                                                       20.6 (436)                  21.6 (10 785)                        20.6 (436)            20.3 (1685)           
   Western                                                        16.7 (353)                  16.1 (8052)                          16.7 (353)            17.5 (1451)           
  Cause of ESKD                                                                                                                                                                
   Diabetes                                                                                   35.7 (18 595)                                              5.5 (452)             
   Ischemic                                                                                   19.6 (10 221)                                              24.7 (2047)           
   Glomerulonephritis                                                                         15.7 (8153)                                                32.7 (2708)           
   Other                                                                                      27.2 (13 571)                                              37.1 (3076)           
  Comorbidities (%, *n*)                                                                                                                                                       
   ACS                                                            7.4 (157)                   18.4 (9214)               **0.33**   7.4 (157)             8.3 (690)             0.03
   Diabetes                                                       6.5 (137)                   48.4 (24 239)             **1.07**   6.5 (137)             6.7 (557)             0.01
   Stroke                                                         6.0 (128)                   13.1 (6561)               **0.24**   6.0 (128)             7.3 (607)             0.05
   PVD                                                            3.5 (75)                    17.1 (8563)               **0.46**   3.5 (75)              4.2 (345)             0.03
   CABG                                                           6.0 (127)                   13.3 (6637)               **0.25**   6.0 (127)             6.3 (518)             0.01
   Cancer                                                         6.2 (132)                   11.9 (5924)               **0.20**   6.2 (132)             7.2 (599)             0.04
   COPD                                                           4.1 (86)                    10.6 (5318)               **0.25**   4.1 (86)              4.5 (374)             0.02
   HTN                                                            73.4 (1558)                 76.2 (38 142)             0.06       73.4 (1556)           79.8 (6613)           **0.15**
   CHF                                                            5.5 (117)                   23.6 (11 784)             **0.53**   5.5 (117)             6.7 (554)             0.05
   Cigarette smoker                                               12.1 (256)                  12.6 (6286)               0.02       12.1 (255)            12.7 (1055)           0.02
   Any serious illness                                            6.9 (2122)                  11.8 (5905)               0.17       6.9 (147)             7.6 (630)             0.03
  Labs (baseline):                                                                                                                                                             
   Hemoglobin (g/L, mean)                                         106.3 (SD 21.4)             100.6 (SD 24.3)           **0.25**   106.3 (SD 21.4)       104.0 (SD 23.7)       **0.10**
   Calcium (mmol/L, mean)                                         2.2 (SD 0.3)                2.3 (SD 0.7)              0.01       2.2 (SD 0.3)          2.1 (SD 0.3)          0.03
   Phosphate (mmol/L, mean)                                       1.0 (SD 3.2)                2.3 (SD 0.8)              0.01       1.4 (SD 2.0)          1.4 (SD 2.5)          0.02
   Albumin (g/L, mean)                                            35.8 (SD 6.0)               32.0 (SD 8.2)             **0.58**   35.8 (SD 6.0)         34.8 (SD 6.0)         **0.15**

*Note.* PS = propensity score; ADPKD = polycystic kidney disease; Stan. D = standardized difference; IQR = interquartile range; ACS = acute coronary syndrome; PVD = peripheral vascular disease; CABG = coronary artery bypass grafting; COPD = chronic obstructive pulmonary disease; HTN = hypertension; CHF = congestive heart failure; ESKD = end-stage kidney disease.

Bold text denotes statistically significant standardized differences.

Regions were categorized as follows: Atlantic (Prince Edward Island, Newfoundland, New Brunswick, Nova Scotia), Central (Ontario), Prairies (Manitoba, Saskatchewan, Alberta), Western (British Columbia).

[Table 2](#table2-2054358118778568){ref-type="table"} presents the differences for the study outcomes between the ADPKD and non-ADPKD population. Preemptive and receipt of any kidney transplant were significantly higher in the ADPKD population compared with non-ADPKD (preemptive: odds ratio \[OR\] = 7.13 95%, confidence interval \[CI\] = 5.74-8.87; any transplant: OR = 2.37, 95% CI = 2.14-2.63). With regard to dialysis, intermittent hemodialysis either as the initial or any dialysis therapy was significantly lower in ADPKD patients (IHD OR = 0.59, 95% CI = 0.54-0.65; any IHD OR = 0.59, 95% CI = 0.53-0.65). PD was similar to the initial RRT modality and was less likely during the course of ESKD for ADPKD patients (PD OR = 1.07, 95% CI = 0.96-1.20; any PD OR = 0.85, 95% CI = 0.77-0.95). There was no difference in short daily hemodialysis use; however, nocturnal hemodialysis was associated with ADPKD as initial or any time during ESKD (nocturnal hemodialysis \[NHD\] OR = 2.74, 95% CI = 1.38-5.44; any NHD OR = 1.53, 95% CI = 1.21-1.93). When examining vascular access results, ADPKD patients were more likely to start with an AVF and if a CVC was used, a permanent catheter (AVF OR = 3.25, 95% CI = 2.79-3.79; permanent CVC OR = 0.68, 95% CI = 0.59-0.79) compared with non-ADPKD patients. All results were consistent with additional sensitivity models adjusting for race, region, predialysis care, hypertension, hemoglobin, and albumin.

###### 

Transplantation, Dialysis Modalities, and Vascular Access at Renal Replacement Therapy Initiation or During the Entire Course of End-Stage Kidney Disease for Propensity Score--Matched ADPKD and Non-ADPKD Patients.

![](10.1177_2054358118778568-table2)

  Outcome                                                                        ADPKD (n = 2120)   Non-ADPKD (8283)   ADPKD              ADPKD^[a](#table-fn5-2054358118778568){ref-type="table-fn"}^
  ------------------------------------------------------------------------------ ------------------ ------------------ ------------------ --------------------------------------------------------------
  Preemptive transplant^[b](#table-fn6-2054358118778568){ref-type="table-fn"}^   11.9 (252)         2.3 (187)          7.13 (5.74-8.87)   7.79 (6.14-9.89)
  Intermittent hemodialysis                                                      57 (1209)          69 (5717)          0.59 (0.54-0.65)   0.79 (0.0.70-0.90)
  Peritoneal dialysis                                                            29.6 (627)         27.8 (2305)        1.07 (0.96-1.20)   1.08 (0.97-1.22)
  Short daily hemodialysis                                                       0.2 (5)            0.2 (22)           0.85 (0.32-2.25)   1.12 (0.39-3.20)
  Nocturnal hemodialysis                                                         0.6 (14)           0.2 (20)           2.74 (1.38-5.44)   2.54 (1.15-5.60)
  Arteriovenous fistula                                                          42.3 (525)         18.7 (1084)        3.25 (2.79-3.79)   2.36 (2.08-2.68)
  Permanent catheter                                                             32.0 (397)         40.2 (2330)        0.68 (0.59-0.79)   0.67 (0.59-0.76)
  Temporary catheter                                                             18.9 (235)         33.9 (1963)        0.49 (0.41-0.57)   0.52 (0.45-0.61)
  Any transplant                                                                 45.8 (971)         27.3 (2262)        2.37 (2.14-2.63)   2.12 (1.89-2.38)
  Any intermittent hemodialysis                                                  69.2 (1,467)       79.4 (6578)        0.59 (0.53-0.65)   0.69 (0.62-0.77)
  Any peritoneal dialysis                                                        34.9 (739)         37.7 (3124)        0.85 (0.77-0.95)   0.86 (0.77-0.96)
  Any short daily hemodialysis                                                   2.5 (54)           2.1 (171)          1.22(0.89-1.65)    1.13 (0.82-1.55)
  Any nocturnal hemodialysis                                                     4.9 (104)          3.2 (266)          1.53 (1.21-1.93)   1.67 (1.31-2.14)

*Note.* ADPKD = polycystic kidney disease; CI = confidence interval.

Additional adjustment for race, region, predialysis care, hypertension, hemoglobin, and albumin.

Preemptive transplant models excluded predialysis care and hypertension.

During the study period, a total of 3362 (ADPKD 445 \[21.0%\], non-ADPKD 2817 \[34.1%\]) patients died. Of those who started IHD as their initial therapy, 26.8% with ADPKD died (324/1209) and 39.0% (2231/5717) without ADPKD died. ADPKD patients treated with IHD as initial therapy were less likely to die compared with non-ADPKD patients (hazard ratio \[HR\] 0.65, 95% CI 0.58-0.73). Of those who started PD as their initial therapy, 17.4% with ADPKD (109/627) died and 24.7% without ADPKD died (570/2305). ADPKD patients whose initial therapy was PD were less likely to die compared with non-ADPKD patients (HR 0.74, 95% CI 0.61-0.89).

Discussion {#section28-2054358118778568}
==========

In this Canadian study using data from the CORR, we found that there were clear differences in renal replacement therapies, dialysis modalities, and vascular access in ADPKD compared with matched non-ADPKD patients. Preemptive and receipt of any kidney transplant were more common in the ADPKD cohort. Nocturnal but not short daily hemodialysis was more likely in ADPKD patients, and PD as a dialysis modality was less likely in ADPKD patients. With respect to vascular access, ADPKD patients were more likely to receive an AVF, whereas non-ADPKD patients were more likely to receive a CVC (whether it be permanent or temporary). Last, survival for ADPKD patients who initiated IHD or PD as a first modality was higher than non-ADPKD patients. Taken together, these findings demonstrate ADPKD patients with ESKD are more likely to receive evidence-based and cost-effective therapies regarding transplant, nocturnal dialysis, and vascular access in Canada but suggest PD may be underutilized.

Transplantation as a means of renal replacement was reported much more in the ADPKD group, both initially and at any point in treatment. This is supported in the literature and may be due to longer timelines for ESKD development or knowledge gain from family members with ESKD.^[@bibr1-2054358118778568],[@bibr4-2054358118778568],[@bibr6-2054358118778568],[@bibr20-2054358118778568][@bibr21-2054358118778568]-[@bibr22-2054358118778568]^ In addition, rates of transplantation in this population appear to be increasing.^[@bibr21-2054358118778568],[@bibr23-2054358118778568]^ Despite adjusting for potentially confounding variables, a patient requiring RRT was over 7 times more likely to initially receive preemptive renal transplantation if they had ADPKD. These data, coupled with the data from similar, large-scale European and US ADPKD studies, further support the notion that renal transplantation is more likely among patients with ADPKD who require RRT.^[@bibr4-2054358118778568],[@bibr5-2054358118778568],[@bibr21-2054358118778568],[@bibr23-2054358118778568]^ Previous reports in Europe and the United States attributed higher kidney transplantation rates in ADPKD patients due to the lack of limiting comorbidities compared with non-ADPKD patients. As our study design eliminated many measurable comorbidity differences between the two groups, other possibilities may include a larger and more willing living donor pool or other unmeasured factors (such as functional status) contributing.

Our findings on PD show that as an initial treatment option, there is no discernable difference between the ADPKD and non-ADPKD groups. However, the receipt of PD at any time throughout the course of treatment was significantly lower in ADPKD patients than in the non-ADPKD patients. It has been hypothesized that PD is relatively less preferred in ADPKD, as a result of decreased intraperitoneal space available for dialysate, as well as increased risk of abdominal herniation.^[@bibr24-2054358118778568],[@bibr25-2054358118778568]^ As such, the choice for PD among ADPKD patients may be inversely proportional to the volume of the kidneys in these patients.^[@bibr26-2054358118778568]^ Other reported concerns include increased abdominal wall herniation, hydrothorax, or risk of peritonitis.^[@bibr27-2054358118778568],[@bibr28-2054358118778568]^ In the United States, PD was reported to be more common in the ADPKD population as a first-line renal replacement than a matched non-ADPKD group.^[@bibr29-2054358118778568]^ Conversely, Spithoven et al reported lower PD use in ADPKD patients albeit in an unmatched study design.^[@bibr4-2054358118778568]^ This suggests other factors may be contributing to the lower PD uptake in the ADPKD population such as a higher likelihood of alternatives such as kidney transplant or home hemodialysis reducing the PD pool. Of concern is the possibility of practice variation. We previously reported considerable practice variation with regard to PD use in Canada, and this may apply directly to ADPKD as regional expertise and physician's beliefs may play a role.^[@bibr30-2054358118778568],[@bibr31-2054358118778568]^ As there are few evidence-based relative contraindications to PD, it should remain a viable and preferred modality for ADPKD patients. In an attempt to retain residual renal function, incremental PD may be a viable option.^[@bibr32-2054358118778568]^ Last, several studies have reported that survival and long-term therapy outcomes of ADPKD patients on PD did not differ significantly against matched non-ADPKD controls,^[@bibr33-2054358118778568],[@bibr34-2054358118778568]^ with 1 study reporting a notably high survival rate.^[@bibr34-2054358118778568]^ This was consistent with our findings that ADPKD patients with PD as an initial therapy demonstrated improved survival compared with non-ADPKD patients.

Nocturnal hemodialysis has numerous benefits over the conventional form of hemodialysis, including fewer cardiac and uremic complications, improved quality of life, and decreased drug usage.^[@bibr35-2054358118778568]^ It has also shown to be relatively equal to conventional hemodialysis with regard to survival, although reports have suggested that extended hemodialysis actually increases survival.^[@bibr36-2054358118778568]^ Our study is the first to look at trends in nocturnal dialysis as related to ADPKD. The present research suggests that in Canada, nocturnal daily hemodialysis is more common among ADPKD patients in ESKD than matched non-ADPKD patients, though it is used infrequently.

While intermittent hemodialysis remained the most prevalent form of RRT overall but the least desirable for a variety of reasons, it was encouraging to find a lower likelihood of its use as an initial therapy or any time among ADPKD patients.^[@bibr37-2054358118778568][@bibr38-2054358118778568]-[@bibr39-2054358118778568]^ However, for ADPKD patients whose initial therapy was IHD, their survival was substantively better than non-ADPKD patients. This finding was consistent with other jurisdictions.^[@bibr1-2054358118778568],[@bibr21-2054358118778568],[@bibr23-2054358118778568]^ With regard to vascular access, AVF is shown to be significantly more prevalent in the ADPKD population, while a CVC is more common in the non-ADPKD population. Previous authors reported similar observations in Europe and the United States.^[@bibr29-2054358118778568],[@bibr40-2054358118778568]^ We further demonstrated a reduced likelihood of temporary CVC use that suggests the initiation of dialysis was likely less acute and planned. Future studies could examine the timing of dialysis initiation in ADPKD patients and the incidence of acute kidney injury (AKI).

Our study has some notable limitations. As ADPKD was identified by the treating physician, as opposed to radiologic imaging or genetic testing, there is a possibility of misclassification. We were unable to capture patients who did not undergo RRT (conservative care). Despite PS matching, the possibility of residual confounding remains as we lacked information on medications, functionality, or patient preference. We did not have data from Quebec, Canada's second largest province. We did not account for longitudinal modality changes or examine the risk of technique failure. The presence of comorbidities in CORR is underestimated, and this may differentially affect the non-ADPKD group more.^[@bibr10-2054358118778568]^ Last, we were unable to examine complications requiring hospitalizations such as infections or cardiac events. Those remain avenues of future investigation.

Conclusions {#section29-2054358118778568}
===========

In a national study, we found ADPKD patients were more likely to receive a kidney transplant, use home hemodialysis, dialyze with an AVF, and have better survival relative to non-ADPKD patients. Conversely, they were less likely to receive any PD during ESKD. This may be attributed to higher transplantation or clinical decision-making processes susceptible to education and intervention.
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